AU2020335930B2 - Oxytocin compositions for treatment of tinnitus - Google Patents

Oxytocin compositions for treatment of tinnitus Download PDF

Info

Publication number
AU2020335930B2
AU2020335930B2 AU2020335930A AU2020335930A AU2020335930B2 AU 2020335930 B2 AU2020335930 B2 AU 2020335930B2 AU 2020335930 A AU2020335930 A AU 2020335930A AU 2020335930 A AU2020335930 A AU 2020335930A AU 2020335930 B2 AU2020335930 B2 AU 2020335930B2
Authority
AU
Australia
Prior art keywords
oxytocin
composition
tinnitus
thickener
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020335930A
Other languages
English (en)
Other versions
AU2020335930A1 (en
Inventor
James CRAMER
Lawrence C. Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maskbegone LLC
Original Assignee
Maskbegone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maskbegone LLC filed Critical Maskbegone LLC
Publication of AU2020335930A1 publication Critical patent/AU2020335930A1/en
Assigned to MASKBEGONE LLC reassignment MASKBEGONE LLC Request for Assignment Assignors: NEW YORK UNIVERSITY
Application granted granted Critical
Publication of AU2020335930B2 publication Critical patent/AU2020335930B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2020335930A 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus Active AU2020335930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893363P 2019-08-29 2019-08-29
US62/893,363 2019-08-29
PCT/US2020/048736 WO2021042029A1 (en) 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus

Publications (2)

Publication Number Publication Date
AU2020335930A1 AU2020335930A1 (en) 2022-03-24
AU2020335930B2 true AU2020335930B2 (en) 2025-06-05

Family

ID=74680528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020335930A Active AU2020335930B2 (en) 2019-08-29 2020-08-31 Oxytocin compositions for treatment of tinnitus

Country Status (7)

Country Link
US (1) US11241477B2 (enExample)
EP (1) EP4021410A4 (enExample)
JP (1) JP2022546703A (enExample)
AU (1) AU2020335930B2 (enExample)
BR (1) BR112022003687A2 (enExample)
CA (1) CA3152988A1 (enExample)
WO (1) WO2021042029A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus
US20250255930A1 (en) * 2024-02-08 2025-08-14 Maskbegone Llc Methods of treatment of tinnitus using derivatives of oxytocin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181880A1 (en) * 2005-08-26 2009-07-16 Yeomans David C Methods for treatment of headaches by administration of oxytocin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167040A1 (en) * 2007-06-07 2010-03-31 MDRNA, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
CN107376071B (zh) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 用于将化合物递送到使用者的上部嗅觉区的喷嘴
US20140066373A1 (en) 2012-08-29 2014-03-06 Albert Einstein College Of Medicine Of Yeshiva University Treating diabetes with oxytocin or oxytocin analogs
US11744838B2 (en) * 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ES2949052T3 (es) * 2014-11-19 2023-09-25 Optinose Inc Administración intranasal
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181880A1 (en) * 2005-08-26 2009-07-16 Yeomans David C Methods for treatment of headaches by administration of oxytocin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AZEVEDO ANDREIA APARECIDA ET AL: "Tinnitus Treatment with Oxytocin: A Pilot Study", FRONTIERS IN NEUROLOGY, 2017, vol. 8, no. 494, pgs. 1- 7, DOI: 10.3389/fneur.2017.00494 *

Also Published As

Publication number Publication date
WO2021042029A1 (en) 2021-03-04
AU2020335930A1 (en) 2022-03-24
US11241477B2 (en) 2022-02-08
JP2022546703A (ja) 2022-11-07
EP4021410A1 (en) 2022-07-06
CA3152988A1 (en) 2021-03-04
BR112022003687A2 (pt) 2022-05-24
EP4021410A4 (en) 2023-12-06
US20210060119A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7756953B2 (ja) マグネシウム含有オキシトシン製剤および使用の方法
JP2021518385A5 (enExample)
US11241477B2 (en) Oxytocin compositions for treatment of tinnitus
JP2022535920A5 (enExample)
AU2016374834A1 (en) Antifungal agent
WO2025171305A1 (en) Methods of treatment of tinnitus using derivatives of oxytocin
US20260053883A1 (en) Oxytocin compositions for treatment of visual snow syndrome
JP2003073303A (ja) 眼局所用液剤の清涼化作用の持続方法
US20070020195A1 (en) Nasally administered appetite suppressants
US20070020194A1 (en) Nasally administered appetite suppressant
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
US20220218627A1 (en) Intranasal administration of ketamine to cluster headache patients
JP7155116B2 (ja) 女性の性機能障害を治療する医薬組成物および方法
US10092630B2 (en) Methods of treating anorexia nervosa by intranasal administration of insulin
US6645532B1 (en) Compositions and method for relieving discomfort in the ears
Class et al. Patent application title: Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction Inventors: Steven Lehrer (New York, NY, US)
US20230190878A1 (en) Beta thymosin peptides for treating viral infections
EP3906934A1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US20140179597A1 (en) Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction
US20030207811A1 (en) Method of treating retinopathy of prematurity using somatostatin analogs
JPWO2006006674A1 (ja) Ｐｔｈを含有する経粘膜投与剤
JP2002338461A (ja) 鼻疾患治療薬
GB2417202A (en) Pharmaceutical preparation comprising calcitonin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MASKBEGONE LLC

Free format text: FORMER APPLICANT(S): NEW YORK UNIVERSITY

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 05 SEP 2025 TO 05 MAR 2026 IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 05 MAR. 2026